Etanercept biosimilar - Mycenax Biotech/TSH Biopharm

Drug Profile

Etanercept biosimilar - Mycenax Biotech/TSH Biopharm

Alternative Names: E11; ENIA11; TuNEX; TuNEX TNFαR-Fc

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Mycenax Biotech; TSH Biopharm
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Feb 2016 TSH Biopharm plans a phase III trial for Ankylosing spondylitis in Taiwan (NCT02685904)
  • 17 Feb 2016 Etanercept biosimilar is still in phase III trial for Rheumatoid arthritis (Mycenax Biotech pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top